Isoliquiritigenin (ISL) and its Formulations: Potential Antitumor Agents

Area of Science:

• Pharmacology
• Natural Products Chemistry
• Oncology

Background:

• Isoliquiritigenin (ISL) is a chalcone derived from plants with diverse pharmacological activities.
• ISL demonstrates significant antitumor properties against various cancer cells in vitro and in vivo.
• The precise mechanisms of ISL's anti-cancer effects and its clinical limitations require further investigation.

Purpose of the Study:

• To provide a comprehensive review of ISL's antitumor pharmacology and mechanisms.
• To focus on ISL's activity in breast cancer cell lines.
• To summarize formulation strategies for enhancing ISL's bioavailability and clinical application.

Main Methods:

• Literature review of pharmacological studies on Isoliquiritigenin.
• Analysis of research on ISL's anti-cancer mechanisms.
• Compilation of formulation development for ISL delivery.

Main Results:

• ISL exhibits potent anti-proliferative and anti-growth effects on cancer cells.
• The review details various molecular mechanisms underlying ISL's antitumor activity.
• Several formulation approaches have been developed to address ISL's poor bioavailability and solubility.

Conclusions:

• Isoliquiritigenin is a promising natural compound with significant antitumor potential, especially for breast cancer.
• Understanding ISL's mechanisms is crucial for optimizing its therapeutic application.
• Formulation advancements are key to overcoming delivery barriers and enabling clinical translation of ISL.